Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease

被引:3
|
作者
Prevots, D. Rebecca [1 ]
Marras, Theodore K. [2 ,3 ]
Wang, Ping [4 ]
Mange, Kevin C. [4 ]
Flume, Patrick A. [5 ]
机构
[1] NIAID, Epidemiol & Populat Studies Unit, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[2] Univ Hlth Network, Dept Resp Med, Toronto, ON, Canada
[3] Univ Toronto, Toronto, ON, Canada
[4] Insmed Inc, Bridgewater, NJ USA
[5] Med Univ South Carolina, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA
基金
美国国家卫生研究院;
关键词
KEY WORDS; hospitalization; nontuberculous mycobacterial pulmonary disease; US Medicare; LUNG-DISEASE; PREVALENCE; MORTALITY;
D O I
10.1016/j.chest.2021.07.034
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Nontuberculous mycobacterial pulmonary disease (NTM-PD) is an uncommon mycobacterial infection characterized by worsening lung function and increased health care resource utilization; however, the overall risk for hospitalization among patients with RESEARCH QUESTION: What is the hospitalization risk among older adults with NTM-PD? STUDY DESIGN AND METHODS: A retrospective, nested, case-control study was conducted by using the Medicare claims database. Cases were defined as patients with $ 2 NTM-PD claims $ 30 days apart between January 1, 2007, and December 31, 2015. The study included individuals aged $ 65 years with $ 12 months of continuous enrollment in both Parts A and B before the first NTM-PD diagnosis. Cases were matched 1:2 to Medicare beneficiaries without NTM-PD (control subjects) according to age and sex. Hospitalizations following the first NTM-PD claim were compared between case and control subjects by using univariate and multivariate analyses. RESULTS: A total of 35,444 case subjects and 65,467 matched control subjects (mean age, 76.6 years; 70% female; $ 87% White) were identified. Baseline comorbidities, particularly pulmonary comorbidities, were more common in case subjects than in control subjects (81.1% vs 17.7% for COPD; 44.6% vs 0.6% for bronchiectasis). All-cause hospitalization was observed in 65.7% of case subjects and 44.9% of control subjects. Unadjusted annual hospitalization rates were significantly (P < .05) greater among case subjects than control subjects. Case subjects also had a significantly shorter time to hospitalization than control subjects. The increased burden due to hospitalization was reflected in multivariate analysis adjusting for baseline comorbidities. All-cause hospitalization in patients with NTM-PD relative to control subjects was 1.2 times more likely (relative risk, 1.23; 95% CI, 1.21-1.25; P < .0001) with a 46% greater hazard (hazard ratio, 1.46; 95% CI, 1.43-1.50; P < .0001). INTERPRETATION: Patients with NTM-PD were significantly more likely to be hospitalized, had greater annualized hospitalization rates, and had shorter time to hospitalization than age- and sex-matched control subjects without NTM-PD. These findings highlight the significantly increased burden of hospitalizations among patients with NTM-PD.
引用
收藏
页码:2042 / 2050
页数:9
相关论文
共 50 条
  • [31] Nonpharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease
    Kim, Hyung-Jun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (04) : 451 - 457
  • [32] THE LUNG MICROBIOME IN NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE
    Kumar, K.
    Cuthbertson, L.
    Ellis, H. C.
    Churchward, C.
    Loebinger, M. R.
    Moffatt, M. F.
    Cookson, W. O. C.
    THORAX, 2022, 77 : A36 - A36
  • [33] Current Therapy for Nontuberculous Mycobacterial Pulmonary Disease
    Hilary P. Steele
    Lisa M. Brumble
    Margaret M. Johnson
    Current Treatment Options in Infectious Diseases, 2015, 7 (4) : 342 - 351
  • [34] Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan
    Namkoong, Ho
    Kurashima, Atsuyuki
    Morimoto, Kozo
    Hoshino, Yoshihiko
    Hasegawa, Naoki
    Ato, Manabu
    Mitarai, Satoshi
    EMERGING INFECTIOUS DISEASES, 2016, 22 (06) : 1116 - 1117
  • [35] Occupational Exposures in Nontuberculous Mycobacterial Pulmonary Disease
    Blanc, Paul D.
    Balmes, John R.
    Redlich, Carrie
    CHEST, 2022, 162 (02) : E106 - E107
  • [36] Nontuberculous Mycobacterial Pulmonary Disease in the Immunocompromised Host
    Varley, Cara D.
    Streifel, Amber C.
    Bair, Amanda M.
    Winthrop, Kevin L.
    CLINICS IN CHEST MEDICINE, 2023, 44 (04) : 829 - 838
  • [37] The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands
    Schildkraut, Jodie Anne
    Zweijpfenning, Sanne Maria Henriette
    Nap, Martijn
    He, Kun
    Dacheva, Elena
    Overbeek, Jetty
    Tostmann, Alma
    Wertheim, Heiman F. L.
    Hoefsloot, Wouter
    van Ingen, Jakko
    ERJ OPEN RESEARCH, 2021, 7 (03)
  • [38] Host Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease
    Namkoong, Ho
    Holland, Steven M.
    CLINICS IN CHEST MEDICINE, 2023, 44 (04) : 723 - 730
  • [39] Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease
    Matsuyama, Masashi
    Matsumura, Sosuke
    Nonaka, Mizu
    Nakajima, Masayuki
    Sakai, Chio
    Arai, Naoki
    Ueda, Kodai
    Hizawa, Nobuyuki
    RESPIRATORY INVESTIGATION, 2023, 61 (02) : 135 - 148
  • [40] Cure rates in nontuberculous mycobacterial pulmonary disease
    Makek, Mateja Jankovic
    Glodic, Goran
    Sabol, Ivan
    Zmak, Ljiljana
    Sola, Ana-Marija
    Marusic, Ante
    Marekovic, Ivana
    Hecimovic, Ana
    Dugac, Andrea Vukic
    Dzubur, Fedja
    Jakopovic, Marko
    Ticac, Brigita
    Bulat, Ljiljana Kardum
    Grle, Sanja Popovic
    Barisic, Blazenka
    Vladic, Vesna Carevic
    Strelec, Drazen
    Pavlisa, Gordana
    Samarzija, Miroslav
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54